Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to -$17.3 million.

  • Tg Therapeutics' Change in Accured Expenses fell 24808.47% to -$17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.9 million, marking a year-over-year decrease of 7593.52%. This contributed to the annual value of $22.8 million for FY2024, which is 75375.7% up from last year.
  • Tg Therapeutics' Change in Accured Expenses amounted to -$17.3 million in Q3 2025, which was down 24808.47% from $5.6 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Change in Accured Expenses high stood at $65.6 million for Q1 2025, and its period low was -$38.0 million during Q4 2024.
  • Over the past 5 years, Tg Therapeutics' median Change in Accured Expenses value was $5.0 million (recorded in 2023), while the average stood at $2.7 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 50173.76% in 2021, then plummeted by 756095.89% in 2022.
  • Quarter analysis of 5 years shows Tg Therapeutics' Change in Accured Expenses stood at -$28.2 million in 2021, then soared by 158.17% to $16.4 million in 2022, then tumbled by 69.27% to $5.0 million in 2023, then plummeted by 853.16% to -$38.0 million in 2024, then soared by 54.54% to -$17.3 million in 2025.
  • Its Change in Accured Expenses was -$17.3 million in Q3 2025, compared to $5.6 million in Q2 2025 and $65.6 million in Q1 2025.